USPTO serial 87626617
ARIA ASSURE RESOURCE FOR INTEGRATED ACCESS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LAVOIE, RYAN CHRISTOPHER
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARIA ASSURE RESOURCE FOR INTEGRATED ACCESS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
B. Brett Heavner
B. BRETT HEAVNER FINNEGAN, HENDERSON, FARARBOW, GARRETT & DUNNER, L901 NEW YORK AVENUE, NWWASHINGTON, DC 20001UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Electronic publications, namely, downloadable brochures and pamphlets about patient support for central nervous system diseases, disorders and treatment and vasopressin receptor antagonist responsive diseases, disorders, and treatment; downloadable video recordings about patient support for central nervous system diseases, disorders and treatment and vasopressin receptor antagonist responsive diseases, disorders, and treatment | ACTIVE | — |
| 016 | Printed materials, namely, brochures, pamphlets and posters about patient support for central nervous system diseases, disorders and treatment and vasopressin receptor antagonist responsive diseases, disorders, and treatment | ACTIVE | — |
| 035 | Promoting awareness of patient support offerings for central nervous system diseases, disorders and treatment and vasopressin receptor antagonist responsive diseases, disorders, and treatment; discharge planning support, namely, providing consumer information to patients about health care plan options, products and programs in the field of managed care and state and federal medical care programs for central nervous system diseases, disorders and treatment and for vasopressin receptor antagonist responsive diseases, disorders, and treatment | ACTIVE | — |
| 036 | Providing financial information about reimbursement for medical expenses for patients with central nervous system diseases and disorders and vasopressin receptor antagonist responsive diseases and disorders; providing insurance information about medical benefit verification and prior authorization services for patients with central nervous system diseases and disorders and vasopressin receptor antagonist responsive diseases and disorders; providing insurance information about medical records coding, billing, and compliance for patients with central nervous system diseases and disorders and vasopressin receptor antagonist responsive diseases and disorders | ACTIVE | — |
| 041 | Educational services, namely, conducting educational programs and providing courses about central nervous system diseases, disorders and treatment; on-line publishing of electronic publications in the nature of user guides; on-line journals, namely, blogs about central nervous system diseases, disorders and treatment and vasopressin receptor antagonist responsive diseases, disorders, and treatment | ACTIVE | — |
| 044 | Providing patient support in the nature of information about the location of medical treatment facilities for central nervous system diseases and disorders and for vasopressin receptor antagonist responsive diseases and disorders; providing medical information to medical professionals in the field of treatment of central nervous system diseases and disorders and of vasopressin receptor antagonist responsive diseases and disorders; providing a website for medical professionals featuring medical information in the field of treatment of central nervous system diseases and disorders and of vasopressin receptor antagonist responsive diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Otsuka America Pharmaceutical, Inc.
- Other trademarks owned by Otsuka America Pharmaceutical, Inc.
- Other trademarks in Class 009
- Other trademarks in Class 016
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named ARIA ASSURE RESOURCE FOR INTEGRATED ACCESS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 8, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 8, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 28, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 26, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 26, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 26, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 12, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 10, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 10, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 10, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 16, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 21, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 21, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 1, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 13, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 12, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 4, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2017 | NWAP | NEW APPLICATION ENTERED | — |